Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Lupus Nephritis(LN) is one of the most serious manifestations of systemic lupus erythematosus.It is a major determinant for both renal and overall outcomes.LN is well studied in developed countries,whereas the data regarding same is scarce in developing countries,especially in southern India.Considering its aggressive disease course, it is imperative to delineate outcomes of various treatment regimens. This retrospective 10 year analysis from a tertiary center in South India aims to provide clinicopathological profile and response to various treatment protocols and their long term outcomes.
It is a retrospective observational study,conducted from January 2012 to December 2022 in department of nephrology.Inclusion criteria comprised all adult patients with biopsy-proven LN with a minimum follow up of 6 months, excluding those with ESRD at presentation,renal allograft recipients.
Out of 2500 renal biopsies conducted between 2012 to 2022 at our institute,175 LN patients were included in study,out of which 85.7% were female.Mean symptom duration was 2 months.The most common presentation was Nephrotic syndrome(43%) followed by Nephritic syndrome(21.1%),RPRF(20.6%). 57.7% had Serum Creatinie >1.5gm/dl and mean 24-h proteinuria was 3.8 ± 2.6 g/day.According to the ISN/RPS 2018 classification, class IV accounted for 53.1% of biopsies,followed by class V 16.6%,class III 14.9%,class IV+V 5.7%.Selection of specific treatment regimen entirely depended on treating clinician preferences. Out of 175 patients,76% of patients received Modified NIH regimen,12% received ELNT & 12% rececievd MMF regimen.62.9% patients received MMF based maintenance regimen and 16.6% received multitargeted therapy.
In our study population,65.7% patients achieved complete remission,while 27.4% attained partial remission,6.9% showed resistance.Although complete remission rates in 3 different induction regimens were comparable(69.2% in NIH ,66.7% in ELNT & 42.9% in MMF ) ,it was not stastically significant (p value=0.049).MMF based maintenance regimen fared well compared to other.
Out of 133 patients who received NIH protocol as induction therapy,19.5% had renal relapses,4.8% on MMF based regimen had lupus flares whereas none in ELNT group.10.3%(n=18) of our study population had mortality. As NIH regimen for induction and MMF based regimen for maintenance was commonly used in our study population,highest mortality was seen these groups 77.8%& 72.2% respectively.
The major limitations of our study were the retrospective nature of data collection,nonuniform treatment regimen selection.
LN in South India commonly presents as nephrotic syndrome primarily in young women as severe proliferative disease. Among induction regimens, modified NIH protocol achieved the highest remission while MMF-based maintenance provided superior long-term stability and lowest relapse.Early diagnosis,relapse prevention and uniform treatment protocols remain critical to improving renal survival.
